Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a post-hoc analysis evaluating the impact of anemia on patient quality of life (QoL) in the Phase III SIMPLIFY-1 and SIMPLIFY-2 trials ( in patients with myelofibrosis (MF). Patients who achieved transfusion independence while taking momelotinib reported an improvement in QoL, highlighting the importance of relieving transfusion burden when treating MF. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть